Genzyme inks royalty-weighted Asian deal for Alnylam's RNAi amyloidosis therapies
This article was originally published in Scrip
Alnylam Pharmaceuticals will receive $22.5 million in cash upfront under a new alliance with Genzyme for the development and commercialisation in Asia of two RNA interfering therapies for transthyretin-mediated amyloidosis (ATTR) disorders.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.